RxDoctor Payments Data

Catherine Sheils, MD

Ophthalmology · San Diego, CANPI 1932605649

Payments from drug & device makers

$13,710in general payments, 2019–2025

Across 209 payments — averaging $65.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$7K
  • AbbVie$2K
  • Alcon$2K
  • Glaukos Corporation$470
  • Biotissue Holdings Inc.$372
  • Rxsight Inc$308
  • plus $967 from 8 others

What the payments were for

  • Speaking & faculty fees$4,00029%
  • Food & beverage$9,71071%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,710 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$296,409
Medicare patients
514
Services billed
2,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost76$41,603
RestasisCyclosporine34$30,805
VyzultaLatanoprostene Bunod71$29,315
Prednisolone Acetate503$23,883
XiidraLifitegrast19$19,862
SimbrinzaBrinzolamide/Brimonidine Tart60$16,827
Alphagan PBrimonidine Tartrate44$14,995
RocklatanNetarsudil Mesylat/Latanoprost26$14,783
RhopressaNetarsudil Mesylate32$13,776
TafluprostTafluprost/Pf62$10,043
Latanoprost682$8,277
Dorzolamide-TimololDorzolamide/Timolol/Pf63$8,134
Brimonidine Tartrate188$7,693
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat418$6,704
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol41$6,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$2,411$93,666178 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$127$49,17790 claims
AlconSimbrinza$2,233$16,82760 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →